SCHEMBL5542804

SCHEMBL5542804

CCOC(=O)N1CCN(c2ccc([O])cc2)CC1

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.77
LMNA P02545 3/20 0.77
GAA P10253 3/20 0.77
KDM4E B2RXH2 1/20 0.77
ALDH1A1 P00352 9/20 0.68
SMN1; SMN2 Q16637 3/20 0.68
HTT P42858 2/20 0.65
MAPK1 P28482 1/20 0.65
HPGD P15428 1/20 0.57
TSHR P16473 1/20 0.57
CASP1 P29466 1/20 0.57
NPSR1 Q6W5P4 1/20 0.57
L3MBTL1 Q9Y468 1/20 0.53
ABL1 P00519 1/20 0.53
POLB P06746 1/20 0.53
RIN1 Q13671 1/20 0.53
TDP1 Q9NUW8 1/20 0.53
KMT2A Q03164 3/20 0.51
MEN1 O00255 2/20 0.51
PDK2 Q15119 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5536205 0.89 MAPT (0.62) MAPTLMNAGAAKDM4EALDH1A1
SCHEMBL15127501 0.89 MAPT (0.79) MAPTLMNAGAAKDM4EALDH1A1
SCHEMBL5542809 0.87 MAPT (1.00) MAPTLMNAGAAKDM4EALDH1A1
SCHEMBL5539965 0.87 MAPT (0.59) MAPTLMNAGAAKDM4EALDH1A1
SCHEMBL2581059 0.86 MAPT (0.75) MAPTLMNAGAAKDM4EALDH1A1
SCHEMBL5541807 0.86 MAPT (0.58) MAPTLMNAGAAKDM4EALDH1A1
SCHEMBL27610366 0.85 MAPT (0.74) MAPTLMNAGAAKDM4EALDH1A1
SCHEMBL5535574 0.84 MAPT (0.57) MAPTLMNAGAAKDM4EALDH1A1
SCHEMBL8557635 0.84 MAPT (0.73) MAPTLMNAGAAKDM4EALDH1A1
SCHEMBL8703730 0.84 MAPT (0.73) MAPTLMNAGAAKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 MAPT 4117/4885LMNA 4152/4885GAA 4165/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.